Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Summary

The primary objectives of this study were to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion), and to evaluate and compare the overall survival of subjects with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) when treated with itacitinib in combination with docetaxel versus docetaxel alone (Part 2, randomized portion).

Timeline

Start

2014-09-24

Primary completion

2016-02

Completion

2016-04-05

Outcome

Outcome not reported

Stopped (Enrollment): “Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.”

Drugs

Indications